What is tirzepatide? It's a weekly GIP and GLP-1 injection sold as Mounjaro and Zepbound for diabetes and weight loss. See how it works and key safety facts.
Tirzepatide is a prescription medication that copies two hormones your gut releases after meals: GIP and GLP-1. It is sold as Mounjaro for type 2 diabetes and as Zepbound for weight management and sleep apnea. Tirzepatide comes as a once-weekly injection and is not available over the counter.
What Does Tirzepatide Do in the Body?
Tirzepatide is a dual GIP and GLP-1 receptor agonist, which means it activates two hormone pathways instead of one. Those pathways prompt the pancreas to release insulin when blood sugar rises, slow the speed at which the stomach empties, and signal the brain to register fullness.
People searching what does tirzepatide do often assume it burns fat directly. It does not. The weight loss comes from eating less and staying satisfied longer, while blood sugar improves because insulin release is better matched to meals.
Because tirzepatide acts on two receptors, most trials show larger average effects on weight and A1C than single-hormone GLP-1 drugs do.
What Is Tirzepatide Used For?
The FDA has approved tirzepatide for three specific conditions:
- Type 2 diabetes: Mounjaro, approved in 2022, helps adults control blood sugar alongside diet and exercise.
- Chronic weight management: Zepbound was approved in 2023 for adults with obesity, or with overweight plus at least one weight-related condition such as high blood pressure or high cholesterol.
- Obstructive sleep apnea: Zepbound was approved in 2024 for moderate-to-severe OSA in adults with obesity, combined with a reduced-calorie diet and more activity.
So when someone asks what is tirzepatide used for, the answer is blood sugar control, weight reduction, and sleep apnea tied to excess weight. Tirzepatide is not FDA-approved for cosmetic weight loss or for people who are already at a healthy body weight.
How Tirzepatide Compares With Semaglutide
Semaglutide (Ozempic, Wegovy, Rybelsus) targets GLP-1 only. Tirzepatide targets GLP-1 and GIP, and that difference shows up clearly in trial results.
| Feature | Tirzepatide | Semaglutide |
|---|---|---|
| Receptors targeted | GIP and GLP-1 | GLP-1 only |
| Brand names | Mounjaro, Zepbound | Ozempic, Wegovy, Rybelsus |
| Typical dosing | Once-weekly injection | Weekly injection or daily pill |
| Average weight loss, head-to-head trial | About 20% of body weight over 72 weeks | About 14% of body weight over 72 weeks |
| Approved for sleep apnea | Yes (Zepbound) | No |
Those averages come from the SURMOUNT-5 head-to-head study; individual results vary widely, and neither medication cures obesity or diabetes.
Anyone comparing the two should understand what is the difference between semaglutide and tirzepatide compound, because compounded versions are not the products tested in those trials and are not FDA-approved.
Dosing, Appearance, and Storage
Tirzepatide starts at 2.5 mg once weekly. The dose then increases roughly every four weeks, up to a maximum of 15 mg weekly, to limit side effects.
| Step | Weekly dose | Typical timing |
|---|---|---|
| Starting dose | 2.5 mg | Weeks 1-4 |
| Second step | 5 mg | Week 5 onward |
| Further steps | 7.5 mg, 10 mg, 12.5 mg | At least 4 weeks apart |
| Maximum dose | 15 mg | Maintenance |
Brand-name tirzepatide is a clear to slightly yellow liquid in a single-dose pen or vial. Patients ask what color is tirzepatide because a cloudy, discolored, or particle-filled solution should never be injected.
Some peptide powders ship dry and must be mixed with a diluent before use, which is why people check what is bacteriostatic water for injection used for and what is bac water, two names for the same preserved sterile water. Keep tirzepatide refrigerated, protect it from light, and discard any pen past its expiration date.
Side Effects and Safety Warnings
The most common side effects are nausea, vomiting, diarrhea, constipation, fatigue, and injection-site reactions. These usually ease as the body adjusts to each new dose.
More serious risks include pancreatitis, gallbladder disease, kidney problems caused by dehydration, and low blood sugar when tirzepatide is combined with insulin or sulfonylureas. The label carries a boxed warning about thyroid C-cell tumors seen in rodents, and tirzepatide is contraindicated for people with a personal or family history of medullary thyroid cancer or MEN2.
Tirzepatide is not recommended during pregnancy or breastfeeding and should be stopped at least two months before a planned pregnancy. Anyone with a history of pancreatitis, kidney disease, or diabetic eye disease should discuss those conditions with a clinician before starting treatment.
Compounded Tirzepatide and Spanish-Language Searches
Compounded tirzepatide became popular during the 2022-2024 supply shortage. Regulators have since restricted large-scale compounding of the drug, and compounded tirzepatide is not FDA-approved, so strength and purity can differ from one pharmacy to the next.
Spanish-speaking searchers often type que es tirzepatide or tirzepatide para que sirve. Both questions mean the same thing: a weekly injectable that improves blood sugar, supports weight loss, and can treat sleep apnea in adults with obesity.
Key Takeaways
- Tirzepatide is a dual GIP and GLP-1 receptor agonist marketed as Mounjaro and Zepbound.
- Tirzepatide is not a cure for diabetes or obesity, and it works only while it is being taken.
- Tirzepatide is not FDA-approved for cosmetic weight loss.
- Compounded tirzepatide is not FDA-approved and is not interchangeable with brand-name pens.
- Anyone considering tirzepatide should talk with a licensed healthcare professional about risks, cost, and monitoring.
Frequently Asked Questions
What is tirzepatide used for?
Tirzepatide is approved to treat type 2 diabetes (as Mounjaro) and for chronic weight management and obstructive sleep apnea in adults with obesity (as Zepbound). It is used together with diet and exercise, not as a replacement for them. It is not approved for cosmetic weight loss.
How much weight can you lose on tirzepatide?
In the SURMOUNT-1 trial, adults on the 15 mg dose lost about 20-22% of their body weight over 72 weeks on average. In the SURMOUNT-5 head-to-head trial, tirzepatide produced roughly 20% weight loss versus about 14% for semaglutide. Individual results vary, and weight often returns if the medication is stopped.
Is tirzepatide the same as Ozempic?
No. Ozempic is semaglutide, which activates only the GLP-1 receptor, while tirzepatide activates both GIP and GLP-1. They are different drugs made by different manufacturers, though both are usually given as once-weekly injections. Only a prescriber can determine which one fits a specific patient.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.